| Serial Number | 97716174 |
| Word Mark | ENLAZA THERAPEUTICS |
| Filing Date | Tuesday, December 13, 2022 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Thursday, July 11, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 30, 2024 |
| Goods and Services | Pharmaceutical products, preparations, and substances for the treatment of cancer; cancer therapeutics, namely, anti-cancer preparations; novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer and tumors; biological preparations and substances for the treatment, diagnosis, detection, and prevention of cancer; pharmaceutical products consisting of covalent protein biologic for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; pharmaceutical products, namely, covalent protein drugs for the treatment of cancer diseases; pharmaceuticals products consisting of synthetic biology enabled covalent protein biologic for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; pharmaceutical products consisting of covalent protein drugs for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals |
| Translation of Words in Mark | The English translation of ENLAZA in the mark is to link, bind or connect. |
| Goods and Services | Reagents for medical research, namely, for therapeutic drug development; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; enzymes for scientific use; cell culture media for use in scientific research for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; active chemical ingredients for use in the manufacture of anti-cancer drugs; laboratory chemicals, namely, an antibody reagent used for the detection of cancerous tumors; antibodies for research use, namely, for therapeutic drug development |
| NOT AVAILABLE | "THERAPEUTICS" |
| Goods and Services | Research and development in the field of covalent protein biologics; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical research and development; research and development of pharmaceuticals and biologicals in the field of cancer therapeutics; research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein drugs; research and development for the purpose of selective covalent modification of proteins; research and development in the field of oncology, namely, development of a biotechnology platform to create covalent protein biologics for treating cancer; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of small-molecule and biologic therapeutics for treating cancer and targeting tumors; conducting clinical trials for others in the field of cancer therapeutics; biotechnology testing services, namely, testing in the field of recombinant protein production and bioconjugation; research and development services in the field of antibody-drug conjugates, T cells, natural killer (NK) cells, and macrophage engaging antibodies; research and development services for the purpose of antibody engineering, namely, custom design and engineering of antibodies |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 10, 2023 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 10, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 10, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Enlaza Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | La Jolla, CA 92037 |
| Party Name | Enlaza Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | La Jolla, CA 92037 |
| Event Date | Event Description |
| Friday, December 16, 2022 | NEW APPLICATION ENTERED |
| Tuesday, January 10, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, September 16, 2023 | ASSIGNED TO EXAMINER |
| Thursday, September 21, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, September 21, 2023 | NON-FINAL ACTION E-MAILED |
| Thursday, September 21, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, November 28, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, November 28, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, November 29, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, March 22, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, March 22, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, January 13, 2024 | NON-FINAL ACTION WRITTEN |
| Saturday, January 13, 2024 | NON-FINAL ACTION E-MAILED |
| Saturday, January 13, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, March 22, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, March 27, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 10, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, April 30, 2024 | PUBLISHED FOR OPPOSITION |
| Wednesday, July 10, 2024 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
| Tuesday, April 30, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, May 29, 2024 | EXTENSION OF TIME TO OPPOSE RECEIVED |